On December 13, 2021, Eric Sawyer filed this petition with the Department of Health and Human Services, asking to join an outstanding march-in petition on the patents for the prostate cancer drug enzalutamide, sold under the brand name Xtandi by… Continue Reading
On Friday, December 3, 2021, KEI requested an open public interest license to allow the exploitation of PF-07321332 (marketed in combination with ritonavir under the brand Paxlovid) in the Dominican Republic. PF-07321332, being developed by Pfizer, has shown promising results… Continue Reading
Today the government of Bolivia and Biolyse, a company based in Canada, signed an agreement to acquire COVID-19 vaccines manufactured by the company, if Canada grants them a compulsory license. Biolyse is a manufacturer of cancer drugs with the potential… Continue Reading
(Update: The NIH provided responses to our comments on April 5, 2021 – 86 FR 10092 Response and 86 FR 10081 Response) On Friday March 5, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institute of Health (NIH)… Continue Reading
In Canada, the foreground intellectual property arising under procurement contracts by default belongs to the contractor. However, there are several exceptions to this rule. One key policy provision allows the government to claim title of the foreground intellectual property “where…… Continue Reading
On Friday, 24 January 2020, South Africa submitted a paper to the World Trade Organization (WTO) TRIPS Council entitled, Intellectual Property and the Public Interest: The WTO TRIPS Agreement and the Copyright Three-Step Test” This submission (document IP/C/W/663), will be… Continue Reading
On September 3, 2019, KEI submitted a request to the NIH that it investigate an apparent failure to disclose federal funding in patents in adeno-associated viral (AAV) gene therapies. A failure to disclose federal funding is a violation of the… Continue Reading
Day 1 of SCCR 38. There is definitely more support for the broadcasting treaty, “a momentum” said a delegate, and it is difficult to find a delegation that would oppose, at least publicly, this 20 year old effort. NGO observers… Continue Reading
PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading
(UPDATE: The NIH provided a response to our comments on April 22, 2019) On February 20, 2019, KEI submitted comments to the Federal Register notice 84 FR 1764 on the “Prospective Grant of an Exclusive Patent License: Use of the… Continue Reading